Should I discontinue hydrochlorothiazide and evaluate for anemia in a patient with a bleeding disorder who has brief light‑headed episodes, a metallic taste, and recent oral bleeding?

Discontinue HCTZ and Evaluate for Anemia Immediately

You were correct to discontinue hydrochlorothiazide, and you must now urgently evaluate this patient for anemia with a complete blood count, ferritin, and iron studies. The combination of lightheadedness, metallic taste (likely blood), increased oral bleeding, and a known bleeding disorder creates a high-risk scenario where anemia is both likely and potentially life-threatening if left unaddressed 1.

Why HCTZ Discontinuation Was Appropriate

Your decision to stop HCTZ due to hypotension was clinically sound. The FDA label explicitly warns that thiazide diuretics can cause orthostatic hypotension, particularly when combined with volume depletion from bleeding 1. In a patient with active bleeding manifestations:

• HCTZ can worsen hypotension through volume depletion, directly contributing to lightheadedness
• The drug's diuretic effect compounds blood loss from the underlying bleeding disorder
• Elderly patients show greater blood pressure reduction and increased side effects with HCTZ 1

Common pitfall: While rare, HCTZ can cause immune hemolytic anemia 2, 3, though this is unlikely given the temporal relationship and presence of a pre-existing bleeding disorder. The more pressing concern is anemia from chronic blood loss.

Immediate Evaluation Protocol

Laboratory Work-Up (Order Today)

1. Complete blood count with differential - assess hemoglobin, hematocrit, MCV
2. Ferritin level - critical for detecting iron deficiency from chronic bleeding
3. Iron studies (serum iron, TIBC, transferrin saturation)
4. Reticulocyte count - distinguish blood loss from production issues

Rationale: Patients with bleeding disorders are at high risk for iron deficiency anemia from acute and chronic blood loss 4. The 2017 Canadian Cardiovascular Society guidelines emphasize that even small reductions in hemoglobin are associated with worse symptoms, increased functional impairment, and reduced quality of life 5. Your patient's lightheadedness occurring after meals (postprandial hypotension exacerbated by anemia) and metallic taste strongly suggest symptomatic anemia.

Clinical Assessment Details

Look specifically for:

• Severity of anemia symptoms: Exercise tolerance, dyspnea on exertion, chest pain (if coronary disease present)
• Bleeding site identification: Oral cavity examination for active bleeding sources, gingival telangiectasias
• Volume status: Orthostatic vital signs (lying, sitting, standing)
• Specific bleeding disorder type: This determines management approach

Management Based on Hemoglobin Results

If Hemoglobin ≥7 g/dL and Asymptomatic

• Oral iron supplementation: Start immediately, even before ferritin results
• Target ferritin >50 ng/mL (higher than general population due to ongoing bleeding risk) 4
• Consider tranexamic acid 500 mg twice daily, titrating to 1000 mg four times daily for oral bleeding control 6

If Hemoglobin <7 g/dL or Symptomatic

• Transfuse RBCs to maintain hemoglobin ≥7 g/dL (≥8 g/dL if coronary disease) 7
• IV iron therapy for faster repletion in moderate-to-severe cases
• Urgent hematology consultation for bleeding disorder optimization

Critical point: Anemia itself worsens bleeding in patients with platelet disorders or von Willebrand disease by disrupting red blood cell rheology and reducing platelet margination to vessel walls 8. Correcting anemia improves hemostasis independent of treating the underlying bleeding disorder.

Bleeding Disorder-Specific Considerations

If von Willebrand Disease or Platelet Disorder

Anemia reduction in RBC mass impairs primary hemostasis, creating a vicious cycle where anemia causes more bleeding, which worsens anemia 8. Aggressive anemia correction is therapeutic, not just supportive.

If Acquired Hemophilia or Factor Deficiency

The 2009 international guidelines recommend immediate immunosuppressive therapy for acquired hemophilia patients 9. However, your patient's chronic course over 4-5 months makes this less likely than a congenital disorder with inadequate iron replacement.

Ongoing Monitoring Strategy

• Hemoglobin and ferritin monthly for first 3 months after iron initiation
• Reassess bleeding symptoms with validated bleeding assessment tools
• Blood pressure monitoring off HCTZ - may need alternative antihypertensive if BP rises (avoid other diuretics that could worsen volume status)

Alternative Antihypertensive Selection

If blood pressure control needed after stabilization:

• ACE inhibitors or ARBs - first choice, no volume depletion
• Calcium channel blockers - second choice
• Avoid all diuretics in setting of active bleeding disorder

Red Flags Requiring Emergency Department Evaluation

Send to ED immediately if:

• Hemoglobin <7 g/dL
• Ongoing hemodynamic instability despite HCTZ discontinuation
• Hemoglobin drop ≥2 g/dL from baseline
• New bleeding at critical sites (intracranial, GI, retroperitoneal)
• Syncope or presyncope

The postprandial timing of lightheadedness suggests splanchnic blood pooling unmasking hypovolemia from anemia - this will improve with hemoglobin correction but requires urgent assessment to rule out severe anemia requiring transfusion 7.